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Summary: Arginase activity of the intestinal mucosa was tested as a proliferative marker in the adenoma-carcinoma
sequence. The enzyme activity was determined by an end-point colorimetric method with L-arginine as substrate.
Arginase activity was evaluated in 430 biopsy samples of large bowel mucosa, polyps and cancer tissue. The
activities (U/g protein, mean ± SE; n) were: normal mucosa 83.2 ± 7.3; 25, adenomas 199.4 ± 19.1; 40, carcino-
mas 1269.7 ± 174.9; 40, inflammatory bowel disease 1210.7 ± 247.1; 34. The arginase activity differs significantly
in the adenoma-carcinoma sequence according to the Duncan's test (p < 0.05).
Introduction
Tumour markers may provide a valuable tool for the
screening and early detection of colorectal neoplasia.
Determination of proliferative markers could be used
for evaluation of the malignancy risk in 'high-risk'
individuals. Activities of enzymes involved in tumour
cell differentiation and proliferation were tested for
this reason. Ornithine decarboxylase (1, 2), urokinase-
type plasminogen activator (3, 4), cathepsin B (5, 6),
tyrosine kinase (1)„ glutathione S-transferase (7), pro-
tein kinase C (8—10), sucrase-isomaltase (11, 12), al-
kaline phosphatase (13), lactate dehydrogenase (14)
and in the last years also arginase (15, 16) activities
were reported. In a previous paper we reported a
significant correlation of the M/H monomer ratio of
lactate dehydrogenase in the colonic mucosa with the
adenoma-carcinoma sequence (17). The aim of this
study was to evaluate arginase activity as a prolifera-




Arginase activity was evaluated in a total of 210 patients who un-
derwent endoscopic polypectomy or biopsy at the Department of
Medicine, Faculty Clinics, Prague. The following groups were
established according to histologic examination: colon cancer
(n = 40), adenomatous polyps (n = 40), inflammatory bowel dis-
ease (n = 34), post-resection anastomosis (n = 17), controls with
normal histology (n = 25). Fourty-four cases remained non-
grouped.
Reproducibility, variations and heterogeneity of arginase determi-
nation were studied on 3 cases.
Case A - normal mucosa; 10 biopsies were taken from the distal
part of colon;
case Β — large adenomatous polyp; 43 mm was cut into 10 parts;
case C — broad sessile polyp; 10 biopsy samples were taken from
the lesion.
The proximodistal gradient of arginase activity was studied in the
group of 11 patients with segmental biopsies along the large bowel.
The following localizations were described: caecum; ascending co-
lon; colon transversum; descending colon; sigmoid; rectum (fig.
1). Only 7 patients with all six tested localizations were used for
final evaluation.
Biopsy sample preparation
Tissue samples of mucosa, polyps or cancers of the large bowel
were obtained endoscopically during colonoscopy using the biopsy
forceps (Olympus Type FB-24 U) or as a part of polyps removed
by polypectomy. Tissue samples were immediately frozen on dry










Fig. 1 Graphical scheme of localizations in the large bowel.
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Biopsy samples were homogenized in 5 mmol Tris-HCl buffer (pH
7.5) containing 100 μηιοΐ/ΐ MnCl2 by using of a glass-homogenizer
for 1 minute in ice-water bath. The homogenized material was
centrifuged at 18000 min"1 for 60 min (refrigerated Janetzki K-
24 centrifuge, 4 °C) and the supernatant was used for enzyme ac-
tivity assay.
Arginase act iv i ty assay
The enzyme activity was determined by our modification of the
procedure described by Konarska (18, 19). Reagent stock solutions
were: 100 mmol/1 arginine (fresh every day), 2 mmol/1 omithine
(stable one month at 4 °C), 25 g/1 ninhydrin (Merck, Germany) in
10 mol/1 acetic acid/2.4 mol/1 phosphoric acid (stable for several
months), 10 mmol/1 MnCl2 (stable for one month).
The incubation of samples was carried out in a water-bath (Lauda,
Germany) at 37 °C for 120 minutes and stopped by immersing
tubes in a boiling water-bath for 5 minutes. The reaction conditions
were as follows: 500 μΐ of 35 mmol/1 Tris-HCl buffer pH 9.5-20
mmol/1 arginine-1 mmol/1 MnCl2 were incubated with 25 μΐ of
homogenate and 25 μΐ of 5 mmol/1 Tris-HCl buffer. The ornithine
concentration was determinated by an end-point ninhydrin reac-
tion, carried out in a boiling water bath for 60 minutes. Ninhydrin
reagent (0.5 ml) and acetic acid (1.5 ml) were added to the incuba-
tion medium. This reaction was stopped by cooling to room-tem-
perature and the colored reaction product was evaluated by using
a double-beam spectrophotometer CE 5000 (Cecil, UK) at 515 nm
in a 1 cm glass cuvette.
Optimal arginine concentration was evaluated from 60 measure-
ments of 5 patients (covering all groups) and arginine concentra-
tions in the range 5-200 mmol/1 (stock solutions) were processed
in duplicate.
Ornithine concentration was calculated from calibration standards
(0.5-2.0 mmol/1 processed with every sample batch. A sample
blank was processed without the 120 minute incubation period for
each test. Wavelength scan was obtained by using a DU-8B spec-
trophotometer (Beckman, USA) in the range of 350-750 nm (scan
speed 100 nm/min).
Arginase activity was expressed in micromoles of ornithine per
minute per gram protein [U/g]. Soluble protein was determined
by the Lowry method using bovine albumin as a calibration pro-
tein.
Statistical evaluation
Results were evaluated by the analysis of variance, Student's
test and Duncan's test (procedures ANOVA, MANOVA) using
the statistical package SPCC PC+ (version 3.1) on a personal
computer. With respect to the asymmetric distribution of data,




Arginase activity in tissue samples was determined by a
two-step method. The first enzymatic reaction produces
L-ornithine from Ζ,-arginine. The concentration of or-
nithine is measured by a colorimetric method with nin-
hydrin. Wavelength scan of the dye produced by the re-
action with ninhydrin showed a peak with a maximum
at 512 nm (fig. 2).
The calibration curve in the range 0-2 mmol/1 of ornith-
ine (fig. 3) is linear and the reaction product is not influ-
enced by MnCl2 used for enzyme activation. The vari-
ance of 0.37% was calculated from a total of 60 mea-
surements (10 times of 6 standards).
Optimal arginine concentration was determined for 100
mmol/1 stock solution. The sigmoid curve was found
in the range of 5 — 100 mmol/1 arginine (fig. 4). A
significant decrease of activity was found in all sam-
ples for 200 mmol/1 arginine concentration. This may
be due to increasing concentration of the reaction pro-
ducts, r
Reproducibility and variations of arginase
The determination of afginase activity in colonic tissue
may be affected mainly by cell heterogeneity and sam-
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Fig. 2 Wavelength scan of coloured ninhydrin reaction product




Fig. 3 Calibration curve of the omithine assay in presence -Q-
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Fig. 4 Arginase activity in U/g protein determined in 5 subjects
[P.B. #, V.T. +, M.R. a, B.S. X, J.V. A] at different arginine
concentration; 5-200 mmol/1 of the stock reagent.
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tested for variations [reproducibility] of arginase activ-
ity. In case A (10 samples of normal mucosa obtained
by biopsy) mean activity ± SE 73.00 U/g ±4.60;
range 55-98, in case B (10 slices of a large adenoma)
the corresponding values were 208.00 ± 17.46; range
157-336, and in case C (10 samples of large sessile
adenoma) 254.50 ± 25.99; range 150-383. The distri-
bution of values around the mean (variance) was
found to be 14.3 times higher for case B and 31.7
times higher in case C compared to case A (normal
mucosa).
Within-run precision of the arginase assay was evaluated
on 50 doublets of tissue homogenate covering the absor-
bance range 0-1.8. Standard deviations of absorbance
were found in the range 0-0.07, corresponding to argi-
nase activity 0-98 kU/1.
The range of normal values of arginase in the colonic
mucosa, 33.1 — 173.7 U/g, was calculated from values of
the control group in logarithmic transformation as
mean ± 2 SD.
Proximodis ta l gradient of enzyme act ivi ty
Arginase activity was determined in 58 mucosal biopsy
samples taken along the large bowel of 11 patients. Indi-
vidual values in the range of 20—180 U/g protein were
plotted for each case against colon localizations (fig. 5).
Four cases with only 4 biopsies (not complete gradient)
were omitted for final evaluation. There were no signifi-
cant changes along the colon, confirming absence of a
proximodistal gradient of arginase activity in the human
large bowel.
Cl inical s ignif icance of arginase activity
The arginase activity (mean ± SE) in five groups (fig. 6)
— colorectal cancer, adenomatous polyps, inflammatory
bowel disease, postresection anastomosis and controls
were 1269.7 ± 174.9, 199.4 ± 19.2, 1210.7 ±247.1,
217.9 ± 110.0, and 83.2 ± 7.3 U/g of protein, respec-
tively. The statistical analysis of variances [Duncan's
test] displayed significant difference between the group
of normal mucosa and all pathological groups
(p < 0.05) as well as between the groups of colorectal
cancer and inflammatory bowel disease and the groups
with adenomas and mucosa of the postresection anasto-
mosis (p < 0.05).
Discussion
Cancer development represents a very complex process
involving different stages defined by biochemical and
histopathological events (20). Several biochemical tu-
mour markers (21) have been tested to support tumour
differential diagnosis, follow-up and early cancer de-
tection. Proteinases, like cathepsin B, D or plasmino-
gen activator, have been proposed to participate in the
metastatic cascade. Ornithine decarboxylase, one of the
rate-limiting enzymes in the polyamine pathway, polya-
mines themselves (putrescine, spermidine, spermine and
cadaverine) have an essential role in cell proliferation
(22). Immunochemical and immunohistochemical meth-
ods are used to prognosticate the risk of cancer reccur-
ence (23, 24). The common main goal of all of these
techniques and methods is to distinguish between nor-
mal, proliferating and carcinomatous mucosa.
Arginase (L-arginine amidinohydrolase, EC 3.5.3.1)
converts L-arginine into L-ornithine and urea. The ele-
vated activity of arginase has been reported in serum as
well as in tissues in colorectal (16, 25, 26), gastric (15)
and mammary (27) carcinomas. The ELISA assay was
developed to evaluate arginase plasma levels (28). This
study was designed to investigate methodological as-
pects of arginase activity determination in the biopsy
sample tissue of colonic mucosa.
Arginase activity in the colonic mucosa is determined
by a two-step method according to Konarska (18, 19).
The concentration of ornithine (as a product of the
first reaction) is measured by a colorimetric method
Fig. 5 Arginase activity in U/g protein determined in 7 subjects
[L. H. X, V. O. A, H. J. o, J. S. *, J. S. #, J. K. 0, J. K. -] at dif-
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Fig. 6 Arginase activity in U/g protein (logarithmic scale) deter-
mined in control group (n = 16), adenomas (n = 38), colorectal
cancer (n = 39), inflammatory diseases (n = 27) and post-resec-
tion anastomosis (n = 16).
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with ninhydrin. We confirmed conditions for the color-
imetric assay by wavelength scan of the end-product
and linearity of the calibration curve. Manganese chlo-
ride used to activate the enzymatic activity (29, 30)
did not affect the assay linearity. Variations of the
ornithine concentration measurement were found to be
less than 1%.
We found no differences in arginase activity along the
large bowel, i.e. there is no proximodistal gradient of
this enzyme in the colonic mucosa. The reproducibility
of the arginase assay in the mucosal samples is consider-
ably influenced by the cell heterogeneity of the tissue
sample. In the normal mucosa the variation amounted to
± 19.9% of the mean activity, in adenomatous polyps
this variation was much higher due to higher cell hetero-
geneity.
High arginase activity was found in the group of colo-
rectal cancer and inflammatory bowel disease. This cor-
responds well with the endeavor to use arginase as a
proliferative marker for colonic mucosa. The significant
differences were found between normal and pathologi-
cally changed mucosa, and between tissue with higher
proliferation (cancer and inflammatory disease) and ad-
enomatous polyps or post-resection mucosa in the large
bowel anastomosis. Further studies are aimed at the
diagnostic efficiency of arginase activity of the colonic
mucosa and at the distribution of this activity in mucosa
surrounding neoplastic lesions.
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